Mettez-vous hors ligne avec l'application Player FM !
Evaluating an Integrative Approach to Treating People with Breast Cancer
Manage episode 322930912 series 1216244
Terri Crudup is an integrative oncology researcher who is passionate about increasing education, support, and funding for integrative therapies. As a two-time cancer survivor, Terri learned the power of complementary and lifestyle therapies, integrating them with traditional treatments to maximize her outcomes. Terri’s employer, IQVIA, sponsored her research study showing institutional involvement with integrative oncology increases the odds of five-year survival for breast cancer patients. Her work has been published through ASCO and in the Journal of Oncology. Terri has a Biology degree from SUNY Geneseo, an MBA from the University of Rochester Simon School, and 20 years’ experience as a researcher and consultant to pharmaceutical companies.
160 episodes
Manage episode 322930912 series 1216244
Terri Crudup is an integrative oncology researcher who is passionate about increasing education, support, and funding for integrative therapies. As a two-time cancer survivor, Terri learned the power of complementary and lifestyle therapies, integrating them with traditional treatments to maximize her outcomes. Terri’s employer, IQVIA, sponsored her research study showing institutional involvement with integrative oncology increases the odds of five-year survival for breast cancer patients. Her work has been published through ASCO and in the Journal of Oncology. Terri has a Biology degree from SUNY Geneseo, an MBA from the University of Rochester Simon School, and 20 years’ experience as a researcher and consultant to pharmaceutical companies.
160 episodes
Tous les épisodes
×Bienvenue sur Lecteur FM!
Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.